Impax, Teva reach settlement with J&J over ADHD drug
Sept 14 (Reuters) - Impax Laboratories Inc and Israel's Teva Pharmaceutical Industries Ltd settled a two-year patent dispute with Johnson & Johnson, allowing the generic drugmakers to start selling a copy of Johnson & Johnson's ADHD drug from July 14, 2013.
In 2010, J&J unit Alza filed a lawsuit to block Impax from launching a copy of Alza's Concerta extended-release tablets that treat attention deficit hyperactivity disorder.
According to Wolters Kluwer Health, U.S. brand and generic sales of Concerta were about $1.2 billion for the 12 months ended July 2012, Impax said in a statement.
The Concerta products are part of Impax's 2001 strategic alliance agreement with Teva. Teva has already filed with U.S. regulators to get approval for a generic version of the drug.
Under the settlement, Alza has agreed to give Impax and Teva a license to sell generic versions of Concerta on July 14, 2013, or earlier under certain circumstances, Impax said.
- Bible left in North Korean sailor's club triggered U.S. tourist's arrest
- Tape emerges of Clinton discussing bin Laden day before 9/11 attack
- U.S. House passes border-security funding bill to speed deportations |
- Israel looks for missing soldier; Hamas says he may have been killed |
- Exposure of health workers weakens Africa's Ebola fight